Create an Account
  1. Home
  2. Specialty
  3. Cataract & Refractive

The Process for Approaching Pseudophakic Monovision in Patients

The Process for Approaching Pseudophakic Monovision in Patients
Media formats available:
Details
Presenters

  • Overview

    In this Master Class, Gerd U. Auffarth, MD, PhD, FEBO, discusses a complex cornea and describes the process for approaching pseudophakic monovision in patients. By the end of this class, you will understand how to apply monovision technology and perform diagnostic tests on patients who have had previous corneal surgery. You will also discover the impact previous surgeries can have and how to choose the right lens to ensure the best patient outcomes.

    This activity is supported by an unrestricted educational grant from AcuFocus.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Define the etiology and prevalence of three most common/impactful complex cornea patient categories that will be featured in this program
    • Describe specific steps and protocols for identifying complex cornea patients, including subjective and objective diagnostics, and how to interpret this information
    • Design an IOL power calculation strategy for complex cornea cases
    • Design treatment plans for the various grades of complex corneas in real-world cases and review conventional and ideal treatment options for these patients

    • Accreditation

      Jointly Provided by Evolve Medical Education and The Fundingsland Group.

                

      Accreditation Statement
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Gerd U. Auffarth, MD, PhD, FEBO

      Gerd U. Auffarth, MD, PhD, FEBO

      Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
      Director (Head), International Vision Correction Research Centre
      Director (Head), David J. Apple Center for Ocular Pathology
      University-Eye Clinic
      Heidelberg, Germany


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Gerd U. Auffarth, MD, PhD, FEBO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, EyeYon Medical, Johnson & Johnson Vision, and VSY. Grant/Research Support: AcuFocus, Alcon, Alimera Sciences, Bausch + Lomb, Biotech, Carl Zeiss Meditec, Contamac, Cristalens, Croma, Eyebright Medical Technology, EyeYon Medical, Hanita Lenses, Hoya Vision, Johnson & Johnson Vision, Kowa, OCULUS, ODC, OpthalmoPro, Ophtec, PhysIOL, Presbia, Rayner, Rheacell, Santen, SIFI, Teleon, Ursapharm, and VSY. Speaker's Bureau: Alcon, Alimera Sciences, Bausch + Lomb, Biotech, Carl Zeiss Meditec, Cristalens, EyeYon Medical, Hoya Vision, Johnson & Johnson Vision, Kowa, OCULUS, Presbia, Rayner, Santen, SIFI, Teleon, Ursapharm, and VSY.

      The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or AcuFocus.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free